Literature DB >> 30023099

EML4-ALK V3, treatment resistance, and survival: refining the diagnosis of ALK+ NSCLC.

Petros Christopoulos1,2, Martina Kirchner2,3, Volker Endris2,3, Albrecht Stenzinger2,3, Michael Thomas1,2.   

Abstract

Entities:  

Year:  2018        PMID： 30023099      PMCID： PMC6036008          DOI： 10.21037/jtd.2018.05.61

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  11 in total

1.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Authors:  Justin F Gainor; Leila Dardaei; Satoshi Yoda; Luc Friboulet; Ignaty Leshchiner; Ryohei Katayama; Ibiayi Dagogo-Jack; Shirish Gadgeel; Katherine Schultz; Manrose Singh; Emily Chin; Melissa Parks; Dana Lee; Richard H DiCecca; Elizabeth Lockerman; Tiffany Huynh; Jennifer Logan; Lauren L Ritterhouse; Long P Le; Ashok Muniappan; Subba Digumarthy; Colleen Channick; Colleen Keyes; Gad Getz; Dora Dias-Santagata; Rebecca S Heist; Jochen Lennerz; Lecia V Sequist; Cyril H Benes; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman; Alice T Shaw
Journal:  Cancer Discov       Date:  2016-07-18       Impact factor: 39.397

2.  Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.

Authors:  Gregory P Kalemkerian; Navneet Narula; Erin B Kennedy; William A Biermann; Jessica Donington; Natasha B Leighl; Madelyn Lew; James Pantelas; Suresh S Ramalingam; Martin Reck; Anjali Saqi; Michael Simoff; Navneet Singh; Baskaran Sundaram
Journal:  J Clin Oncol       Date:  2018-02-05       Impact factor: 44.544

3.  High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer.

Authors:  Nicole Pfarr; Albrecht Stenzinger; Roland Penzel; Arne Warth; Hendrik Dienemann; Peter Schirmacher; Wilko Weichert; Volker Endris
Journal:  Genes Chromosomes Cancer       Date:  2015-09-23       Impact factor: 5.006

4.  Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.

Authors:  Ka-Won Noh; Mi-Sook Lee; Seung Eun Lee; Ji-Young Song; Hyun-Tae Shin; Yu Jin Kim; Doo Yi Oh; Kyungsoo Jung; Minjung Sung; Mingi Kim; Sungbin An; Joungho Han; Young Mog Shim; Jae Ill Zo; Jhingook Kim; Woong-Yang Park; Se-Hoon Lee; Yoon-La Choi
Journal:  J Pathol       Date:  2017-09-28       Impact factor: 7.996

5.  Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Dara L Aisner; Maria E Arcila; Mary Beth Beasley; Eric H Bernicker; Carol Colasacco; Sanja Dacic; Fred R Hirsch; Keith Kerr; David J Kwiatkowski; Marc Ladanyi; Jan A Nowak; Lynette Sholl; Robyn Temple-Smolkin; Benjamin Solomon; Lesley H Souter; Erik Thunnissen; Ming S Tsao; Christina B Ventura; Murry W Wynes; Yasushi Yatabe
Journal:  J Mol Diagn       Date:  2018-01-23       Impact factor: 5.568

6.  Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

Authors:  Jessica J Lin; Viola W Zhu; Satoshi Yoda; Beow Y Yeap; Alexa B Schrock; Ibiayi Dagogo-Jack; Nicholas A Jessop; Ginger Y Jiang; Long P Le; Kyle Gowen; Philip J Stephens; Jeffrey S Ross; Siraj M Ali; Vincent A Miller; Melissa L Johnson; Christine M Lovly; Aaron N Hata; Justin F Gainor; Anthony J Iafrate; Alice T Shaw; Sai-Hong Ignatius Ou
Journal:  J Clin Oncol       Date:  2018-01-26       Impact factor: 44.544

7.  Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

Authors:  Johannes M Heuckmann; Hyatt Balke-Want; Florian Malchers; Martin Peifer; Martin L Sos; Mirjam Koker; Lydia Meder; Christine M Lovly; Lukas C Heukamp; William Pao; Ralf Küppers; Roman K Thomas
Journal:  Clin Cancer Res       Date:  2012-08-21       Impact factor: 12.531

8.  Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.

Authors:  C G Woo; S Seo; S W Kim; S J Jang; K S Park; J Y Song; B Lee; M W Richards; R Bayliss; D H Lee; J Choi
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

9.  Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.

Authors:  Michaël Duruisseaux; Benjamin Besse; Jacques Cadranel; Maurice Pérol; Bertrand Mennecier; Laurence Bigay-Game; Renaud Descourt; Eric Dansin; Clarisse Audigier-Valette; Lionel Moreau; José Hureaux; Remi Veillon; Josiane Otto; Anne Madroszyk-Flandin; Alexis Cortot; François Guichard; Pascaline Boudou-Rouquette; Alexandra Langlais; Pascale Missy; Franck Morin; Denis Moro-Sibilot
Journal:  Oncotarget       Date:  2017-03-28

10.  Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain.

Authors:  Mark W Richards; Edward W P Law; La'Verne P Rennalls; Sara Busacca; Laura O'Regan; Andrew M Fry; Dean A Fennell; Richard Bayliss
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-24       Impact factor: 11.205
View more
  9 in total

1.  Liquid biopsies come of age in lung cancer.

Authors:  Petros Christopoulos
Journal:  Transl Lung Cancer Res       Date:  2022-05

2.  Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib.

Authors:  Julia Kunz; Christiane Wiedemann; Heidrun Grosch; Katharina Kriegsmann; Stefanie Gryzik; Julia Felden; Michael Hundemer; Huriye Seker-Cin; Miriam Stenzinger; Albrecht Leo; Albrecht Stenzinger; Michael Thomas; Petros Christopoulos
Journal:  Cancers (Basel)       Date:  2022-05-31       Impact factor: 6.575

3.  Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib.

Authors:  Jingjing Li; Bin Zhang; Yu Zhang; Feng Xu; Zhenfa Zhang; Lin Shao; Chunhe Yan; Paola Ulivi; Marc G Denis; Petros Christopoulos; Vincent Thomas de Montpréville; Eric H Bernicker; Anthonie J van der Wekken; Changli Wang; Dongsheng Yue
Journal:  Transl Lung Cancer Res       Date:  2021-03

Review 4.  Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib.

Authors:  Erika Rijavec; Federica Biello; Alice Indini; Francesco Grossi; Carlo Genova
Journal:  Clin Pharmacol       Date:  2022-01-20

5.  High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report.

Authors:  Yan Li; Peng Duan; Yan Guan; Qing Chen; Anna Grenda; Petros Christopoulos; Marc G Denis; Qisen Guo
Journal:  Transl Lung Cancer Res       Date:  2022-01

6.  A novel quantitative prognostic model for initially diagnosed non-small cell lung cancer with brain metastases.

Authors:  Xiaohui Li; Wenshen Gu; Yijun Liu; Xiaoyan Wen; Liru Tian; Shumei Yan; Shulin Chen
Journal:  Cancer Cell Int       Date:  2022-08-11       Impact factor: 6.429

7.  Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1-ALK-rearranged lung cancer.

Authors:  Steffen Dietz; Petros Christopoulos; Albrecht Stenzinger; Holger Sültmann; Lisa Gu; Anna-Lena Volckmar; Volker Endris; Zhao Yuan; Simon J Ogrodnik; Tomasz Zemojtel; Claus-Peter Heussel; Marc A Schneider; Michael Meister; Thomas Muley; Martin Reck; Matthias Schlesner; Michael Thomas
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-12-13

8.  Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies.

Authors:  Petros Christopoulos; Steffen Dietz; Arlou K Angeles; Stephan Rheinheimer; Daniel Kazdal; Anna-Lena Volckmar; Florian Janke; Volker Endris; Michael Meister; Mark Kriegsmann; Thomasz Zemojtel; Martin Reck; Albrecht Stenzinger; Michael Thomas; Holger Sültmann
Journal:  Transl Lung Cancer Res       Date:  2021-05

9.  Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis.

Authors:  Arlou Kristina Angeles; Petros Christopoulos; Zhao Yuan; Simone Bauer; Florian Janke; Simon John Ogrodnik; Martin Reck; Matthias Schlesner; Michael Meister; Marc A Schneider; Steffen Dietz; Albrecht Stenzinger; Michael Thomas; Holger Sültmann
Journal:  NPJ Precis Oncol       Date:  2021-12-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.